- Max Healthcare’s net income for the first quarter was 3.08 billion rupees, reflecting a 31% increase compared to the previous year, but fell short of the estimated 3.65 billion rupees.
- The company’s revenue reached 20.3 billion rupees, marking a 32% year-over-year increase, yet it was below the expected 23.62 billion rupees.
- Total costs amounted to 16.6 billion rupees, also representing a 32% growth year-over-year.
- Operating EBITDA rose by 23% year-over-year to 6.13 billion rupees.
- Max Healthcare plans to lease space from Goyal Agrim Infra Realty LLP for a new approximately 130-bed hospital in Dehradun, Uttarakhand.
- A new 160-bed tower at Max Mohali is complete, with trial-runs initiated on two floors in July.
- Jaypee Healthcare, a unit of Max Healthcare, signed a binding term sheet to divest Chitta Bulandshahr and Anoopshahr hospitals for 400 million rupees.
- Investment analyst recommendations include 16 buys, 3 holds, and 5 sells for Max Healthcare stock.
Max Healthcare Institute on Smartkarma
Analysts on Smartkarma have differing opinions on Max Healthcare Institute. Janaghan Jeyakumar, CFA, and Brian Freitas are bullish on the company, foreseeing potential upside. Jeyakumar notes the likelihood of Max Healthcare being added to the NIFTY Index, indicating further growth prospects. Meanwhile, Freitas highlights Max Healthcare’s solid performance and the possibility of significant future gains. Conversely, Avien Pillay takes a bearish stance, citing concerns over Max Healthcare’s valuation and competitive challenges in the Indian hospital sector. Despite varied sentiments, these reports provide investors with valuable insights to consider.
A look at Max Healthcare Institute Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Max Healthcare Institute Limited, a leading hospital chain in India, has received promising Smart Scores across different aspects. With strong scores in Growth, Resilience, and Momentum, the company appears well-positioned for long-term success. A high Growth score indicates the potential for expansion and financial progress, while Resilience and Momentum scores suggest stability and positive market sentiment. Despite average scores in Value and Dividend, the overall outlook for Max Healthcare Institute seems optimistic, driven by its robust performance in key areas.
Max Healthcare Institute Limited, known for its wide range of specialized medical services, continues to showcase its strength in the healthcare sector. Offering services such as urology, oncology, orthopaedics, and more, the company caters to diverse medical needs in India. With favorable ratings in Growth, Resilience, and Momentum, Max Healthcare Institute is anticipated to thrive in the long run. Investors may find the company attractive due to its strong performance indicators pointing towards sustained growth and resilience in the competitive healthcare landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
